Purchase Order VA580N11637
Award Date 10/14/10
Potential Completion Date 11/14/11
Potential Value $4.8K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Scottsdale, AZ 85257, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This federal contract award was issued by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a privately held medical technology company, for the provision of the Provant Therapy System, a noninvasive regenerative medicine product. The $4,820.98 firm-fixed-price purchase order contract was awarded on January 10, 2011, with a completion date of February 10, 2011. The contract was awarded under Regenesis Biomedical's General Services Administration (GSA) Schedule 65-II-A for...
- This federal contract award is for the procurement of the Provant Therapy System, a noninvasive regenerative medicine product developed by Regenesis Biomedical Inc. The contract, valued at $4,820.98, was awarded to Regenesis Biomedical Inc. by the Department of Veterans Affairs (VA) on June 21, 2011, with an ultimate completion date of July 21, 2011. The contract is a firm fixed-price purchase order, and it does not utilize any set-aside designations. Regenesis Biomedical Inc. is the prime...
- This federal contract award was issued by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a privately held medical technology company. The $4,820.98 firm fixed-price purchase order is for the Provant Therapy System, a noninvasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract has an ultimate completion date of January 20, 2011. Regenesis Biomedical has provided the Provant Therapy System and related rental...
- This federal contract award was issued by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a privately held medical technology company. The $4,820.98 firm-fixed-price purchase order is for the company's Provant Therapy System, a noninvasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract has an ultimate completion date of May 8, 2011 and was awarded through Regenesis Biomedical's existing GSA Schedule...
- This federal contract award was made by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a privately held medical technology company. The $3,645.14 firm fixed-price purchase order is for the Provant Therapy System, a noninvasive regenerative medicine product developed and patented by Regenesis Biomedical. The contract has an ultimate completion date of March 25, 2011. This award was made against Regenesis Biomedical's General Services Administration (GSA) Schedule 65-II-A...
- This federal contract award to Regenesis Biomedical Inc. was made by the Department of Veterans Affairs (VA) for the provision of the Provant Therapy System, a noninvasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The $3,645.14 firm fixed-price purchase order contract has a completion date of June 16, 2011. Regenesis Biomedical is the prime contractor providing its proprietary medical device directly to the VA, with no subcontractors...
- This federal contract award is for the purchase of the Provant Therapy System from Regenesis Biomedical Inc., a medical technology company. The $4,820.98 firm fixed-price purchase order was awarded by the U.S. Department of Veterans Affairs (VA) on December 28, 2010, with an ultimate completion date of January 28, 2011. The contract was awarded against Regenesis Biomedical's existing GSA Schedule 65-II-A contract for medical equipment and supplies, and did not utilize any set-aside designations....
- This federal contract award was made by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a privately held medical technology company. The $7,142.85 firm fixed-price purchase order contract is for the provision of Regenesis Biomedical's Provant Therapy System, a patented noninvasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract is not associated with any set-aside designations. Regenesis Biomedical,...
- This federal contract award to Regenesis Biomedical Inc. is for the supply of the company's Provant Therapy System medical device and related rental/leasing services to the U.S. Department of Veterans Affairs (VA). The $4,882.79 firm-fixed-price purchase order was awarded on February 16, 2011, with a completion date of March 16, 2011. The contract was awarded against Regenesis Biomedical's existing General Services Administration (GSA) Schedule 65-II-A contract for medical equipment and...
- This is a firm fixed-price purchase order contract awarded by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a for-profit medical technology company. The $4,820.98 contract is for the Provant Therapy System, a patented non-invasive regenerative medicine product indicated for post-operative pain and edema treatment. The contract was awarded under Regenesis Biomedical's existing General Services Administration (GSA) Schedule 65-II-A contract for medical equipment and...